Wealthcare Advisory Partners LLC Has $11.78 Million Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Wealthcare Advisory Partners LLC decreased its position in shares of Johnson & Johnson (NYSE:JNJ) by 1.8% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 71,056 shares of the company’s stock after selling 1,294 shares during the period. Wealthcare Advisory Partners LLC’s holdings in Johnson & Johnson were worth $11,784,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also made changes to their positions in the company. Lantz Financial LLC boosted its position in shares of Johnson & Johnson by 3.3% during the 1st quarter. Lantz Financial LLC now owns 11,974 shares of the company’s stock worth $1,986,000 after acquiring an additional 377 shares in the last quarter. Sulzberger Capital Advisors Inc. acquired a new stake in shares of Johnson & Johnson during the 4th quarter worth approximately $453,000. Horan Securities Inc. boosted its position in shares of Johnson & Johnson by 1.3% during the 4th quarter. Horan Securities Inc. now owns 7,178 shares of the company’s stock worth $1,038,000 after acquiring an additional 90 shares in the last quarter. Strategic Financial Concepts LLC boosted its position in shares of Johnson & Johnson by 57.9% during the 4th quarter. Strategic Financial Concepts LLC now owns 3,467 shares of the company’s stock worth $501,000 after acquiring an additional 1,271 shares in the last quarter. Finally, State of Wyoming boosted its position in shares of Johnson & Johnson by 205,580.0% during the 4th quarter. State of Wyoming now owns 10,284 shares of the company’s stock worth $1,487,000 after acquiring an additional 10,279 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently commented on JNJ. The Goldman Sachs Group raised shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and increased their price objective for the company from $157.00 to $172.00 in a research note on Wednesday, April 9th. Barclays dropped their price objective on shares of Johnson & Johnson from $166.00 to $165.00 and set an “equal weight” rating for the company in a research note on Thursday, April 17th. Leerink Partners downgraded shares of Johnson & Johnson from an “outperform” rating to a “market perform” rating and dropped their price objective for the company from $169.00 to $153.00 in a research note on Tuesday, May 13th. Sanford C. Bernstein reissued a “market perform” rating on shares of Johnson & Johnson in a research note on Wednesday, April 16th. Finally, Morgan Stanley increased their price objective on shares of Johnson & Johnson from $164.00 to $169.00 and gave the company an “equal weight” rating in a research note on Wednesday, April 16th. Eleven analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, Johnson & Johnson has a consensus rating of “Moderate Buy” and an average price target of $170.88.

Johnson & Johnson Price Performance

JNJ stock opened at $155.19 on Tuesday. The company has a fifty day moving average price of $153.59 and a 200-day moving average price of $153.67. The company has a market capitalization of $373.40 billion, a P/E ratio of 23.34, a PEG ratio of 2.56 and a beta of 0.42. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $169.99. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.59 by $0.18. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The firm had revenue of $21.89 billion during the quarter, compared to the consensus estimate of $21.65 billion. As a group, equities analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th will be paid a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 3.35%. The ex-dividend date is Tuesday, May 27th. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.24. Johnson & Johnson’s dividend payout ratio (DPR) is currently 57.84%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.